Companies: 10,795·Total market cap: $144.5T
Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc.

BCLIOTCHealthcare● Active
$0.80
+$0.05(+6.87%)
Market Cap$8827820
P/E Ratio—
52W High$1.33
52W Low$0.46
SEC Filings

Brainstorm Cell Therapeutics Inc. (BCLI) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001137883 · BCLI · OTC · as of Jun 8, 2026

Filing snapshot

942
Total Filings
3
Latest Form
2026-06-03
Most Recent
2003
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001137883 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-31
Fiscal Year End
Mar 31, 2026
Accession No.
0001104659-26-037927
Primary Document
bcli-20251231x10k.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001137883 · Accession 0001104659-26-037927

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-15
View 10-Q on SEC
8-KCurrent Report
FORM 8-K
2026-05-28Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
3Initial Statement of Beneficial Ownership
OWNERSHIP DOCUMENT
2026-06-03
View
EFFECTEFFECT
EFFECT
2026-06-02
View
8-KCurrent Report
FORM 8-K
2026-05-28
View
S-8Employee Stock Plan Registration
FORM S-8
2026-05-21
View
S-1IPO Registration Statement
S-1
2026-05-21
View
8-KCurrent Report
FORM 8-K
2026-05-15
View
10-QQuarterly Report
10-Q
2026-05-15
View
10-KAnnual Report
10-K
2026-03-31
View
8-KCurrent Report
FORM 8-K
2026-03-31
View
8-KCurrent Report
FORM 8-K
2026-02-27
View
8-KCurrent Report
FORM 8-K
2026-02-13
View
8-KCurrent Report
FORM 8-K
2026-01-09
View
10-QQuarterly Report
10-Q
2025-11-14
View
8-KCurrent Report
FORM 8-K
2025-11-14
View
8-KCurrent Report
FORM 8-K
2025-11-06
View
Showing 1–15 of 667 filingsForm 4 / 144 hidden· 942 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001137883  |  Exchange: OTC · Healthcare

Brainstorm Cell Therapeutics Inc. (OTC: BCLI) has submitted 942 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2003. As a Healthcare sector company with CIK 0001137883, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Brainstorm Cell Therapeutics Inc.'s most comprehensive regulatory disclosure. The most recent Brainstorm Cell Therapeutics Inc. 10-K was filed on 2026-03-31 for fiscal year ending 2026. Historical BCLI 10-K annual reports are available from 2001 through 2026.

Investors researching Brainstorm Cell Therapeutics Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
NRSN SEC Filings →VYNE SEC Filings →IBO SEC Filings →BCDA SEC Filings →ADXN SEC Filings →MTNB SEC Filings →CDIO SEC Filings →HCWB SEC Filings →
→ BCLI Financials→ BCLI Earnings→ BCLI Insider Trades

Frequently Asked Questions

BCLI SEC Filings · 8 questions

Brainstorm Cell Therapeutics Inc. (BCLI) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 942 filings and access original documents at no cost. Brainstorm Cell Therapeutics Inc.'s CIK is 0001137883.

BCLI SEC filingsBrainstorm Cell Therapeutics Inc. SEC documentsfind BCLI 10-K